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Research over the last decade strengthened the understanding that skeletal muscles are
not only the major tissue in the body from a volume point of view but also function as
a master regulator contributing to optimal organismal health. These new contributions to
the available body of knowledge triggered great interest in the roles of skeletal muscle
beyond contraction. The World Health Organization, through its Global Burden of Disease
(GBD) report, recently raised further awareness about the key importance of skeletal
muscles as the GDB reported musculoskeletal (MSK) diseases have become the second
greatest cause of disability, with more than 1.7 billion people in the globe affected by a
diversity of MSK conditions. Besides their role in MSK disorders, skeletal muscles are also
seen as principal metabolic organs with essential contributions to metabolic disorders,
especially those linked to physical inactivity. In this review, we have focused on the unique
function of new genes/proteins (i.e., MTMR14, MG29, sarcalumenin, KLF15) that during
the last few years have helped provide novel insights about muscle function in health and
disease, muscle fatigue, muscle metabolism, and muscle aging. Next, we provide an in
depth discussion of how these genes/proteins converge into a common function of acting
as regulators of intracellular calcium homeostasis. A clear link between dysfunctional
calcium homeostasis is established and the special role of store-operated calcium entry is
analyzed. The new knowledge that has been generated by the understanding of the roles
of previously unknown modulatory genes of the skeletal muscle excitation-contraction
coupling (ECC) process brings exciting new possibilities for treatment of MSK diseases,
muscle regeneration, and skeletal muscle tissue engineering. The next decade of skeletal
muscle and MSK research is bound to bring to fruition applied knowledge that will
hopefully offset the current heavy and sad burden of MSK diseases on the planet.
Keywords: musculoskeletal diseases, MG29, MTMR14, sarcalumenin, KLF15, calcium homeostasis, sarcopenia,
aging
INTRODUCTION TO THE GLOBAL PROBLEM
The Global Burden of Disease Study (GBD) of 2010 estimates
1.7 billion people worldwide are affected by musculoskeletal dis-
orders (MSDs). Among the almost 300 diseases and injuries
evaluated in the GBD study of 2010, MSDs rank as the second
greatest cause of disability according to the calculated years lived
with disability (YLDs) for affected individuals. This equates to
roughly 21.3% of all YLDs. MSDs only rank below mental and
behavioral disorders with respect to this measure. Between 1990
and 2010, a 44.7% increase in the YLDs of musculoskeletal disor-
ders was observed (Vos et al., 2010).When disorders are evaluated
in terms of disability-adjusted life years (DALYs), MSDs ranked
fourth below cardiovascular diseases, neoplasms, and mental dis-
orders. DALYs give a more accurate representation of the drivers
of poor health by accounting for both disability and death asso-
ciated with a disorder rather than basing the impact solely on
the number of deaths over time. In 2010, MSDs accounted for
roughly 6.8% of total DALYs globally which increased from the
estimated 4.7% in 1990 (Murray et al., 2010). The distribution
and impact of MSDs is relatively equal globally as these condi-
tions are not considered indigenous to a specific region. The GBD
of 2010 suggests that healthcare systems need to focus on devel-
oping a policy to deal with the increasing burden caused byMSDs
(Murray et al., 2010; Vos et al., 2010).
Musculoskeletal disorders include a variety of conditions that
affect muscles, bones, and joints throughout the body. The impact
of MSDs on daily life ranges from minimal discomfort to debil-
itating pain that considerably affects the performance of simple
everyday activities. In terms of severity, MSDs encompass a broad
spectrum of symptoms ranging from minor conditions to major
disorders, including arthritis, back and neck pain, and muscle
wasting disorders. In this review we will focus on some of the
most severe of these disorders, specifically skeletal muscle wast-
ing disorders that have the broadest impact on human health and
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patient outcomes. The increased prevalence of muscle wasting
disorders appears to be in part due to the increasing life span
of humans with age as a contributing factor in approximately
one-third of documented MSDs (561 million people). A 49.9%
increase in DALYs between 1990 and 2010 was observed for all
types of muscle wasting disorders, which is slightly larger than
the change observed for MSDs in general (Murray et al., 2010).
Muscle wasting is a comorbidity of the ever increasing conditions
of heart failure and cancer in addition to its association with skele-
tal muscle disorders. With its rise in prevalence, muscle wasting
disorders and their underlying mechanisms are of great impor-
tance in an effort to provide appropriate treatments (Teixeira
Vde et al., 2012). While multiple MSDs contribute to changes in
human health, skeletal muscle wasting will be the major focus of
this review.
MUSCLE WASTING DISORDERS
MUSCLE WASTING IS MUCH MORE THAN MUSCLE LOSS
In skeletal muscle, the number of cells (muscle fibers) present
in an anatomical muscle stabilizes early in life and remains con-
stant into adulthood, after which time increased muscle mass
and strength is dependent on an increase in the size of muscle
fibers (hypertrophy). Injured muscle fibers can be repaired or
replaced by activation of neighboring satellite cells that will pro-
liferate and repair damaged muscle fibers. A decrease in muscle
fiber size is a factor contributing to muscle weakness. While mus-
cle weakness is a shared characteristic of many skeletal muscle
wasting disorders including atrophy, sarcopenia, myopathy, and
others, the long term outcome of these disorders in addition to
the biochemical andmolecular processes driving them can be dis-
tinct (Romanick et al., 2013). For this reason, further research on
the mechanisms behind each disorder and evaluation of possible
therapeutic interventions for the associated muscle weakness is of
vital importance.
Atrophy is the loss of myofiber size and quantity most com-
monly due to disuse of muscles (Lexell, 1993; Brooks and
Faulkner, 1994; Schakman et al., 2013). While the pathophysi-
ological effects of atrophy caused by inactivity can typically be
restored by physical activity, these effects are not easily reversed
in situations such as sarcopenia and other muscle wasting dis-
orders (Faulkner et al., 1995; Bortz and Bortz, 1996; Gonzalez
et al., 2000; Zahn et al., 2006; Romero-Suarez et al., 2010). In these
conditions, recovery of muscle strength caused by the functional
and physical loss of muscle fibers is very difficult. This contin-
ued and irreversible detrimental effect on muscle fibers leads to
fragility and eventually hinders the quality of life and indepen-
dence of individuals. Sarcopenia has been specifically referred to
as muscle atrophy and wasting that accompanies aging. A variety
of molecular targets and processes proposed to be involved in sar-
copenia include muscle proteolysis, increased cellular autophagy,
aberrant activation of Ca2+-activated proteases and proteasomes,
and dysfunction or loss of satellite cells (Teixeira Vde et al., 2012;
Romanick et al., 2013). While sarcopenia is considered a nor-
mal part of healthy aging, studies suggest that the progression
of sarcopenia can be slowed if the specific molecular process
responsible for its pathophysiological effects can be determined
and specifically targeted (Romanick et al., 2013). In fact, the
complexity of these diseases associated with muscle wasting is
further compounded by an intriguing signature where muscle
mass does not necessarily match functional status (i.e. muscle
contractile force and muscle power) (Lowe et al., 2002, 2004;
Romero-Suarez et al., 2010; Manini and Clark, 2012; Russ et al.,
2012). Multiple factors contribute to this phenomenon, including
increased fatty infiltration and an increased prevalence of myosin
type I expression in aging skeletal muscle. While the loss of mus-
cle mass itself is detrimental to health because of its obvious
metabolic consequences, the loss of functional capacity surpasses
the muscle content loss and aggravates these conditions (Lowe
et al., 2002, 2004; Mitchell et al., 2012; Romanick et al., 2013).
It is important to distinguish between muscle wasting and
muscle weakness that can be two distinct processes involving loss
of muscle mass or loss of functional muscle output respectively.
Muscle weakness itself is a major contributor to morbidity, risk
of falls, and mortality (Brotto and Abreu, 2012). Our research
groups have proposed since the early 2000’s that the definition
of sarcopenia for example must not be limited to “loss of muscle
mass.” It is still puzzling that despite many recent efforts sarcope-
nia is not defined as a disease; an International Disease Code
(IDC) still does not exist for sarcopenia, which should be defined
as a disease of aging characterized by a loss of muscle strength
that surpasses the loss of muscle mass. Muscle fatigue is another
essential characteristic of muscle that is commonly affected in
muscle wasting disorders and in the aging process. In general,
muscle fatigue is defined as a reversible decline in the ability of
a muscle to create force either due to repetitive or continued
activity. Muscle fatigue is thought to be a biological process to
minimize damage to muscles that is produced by overexertion;
however, the exact cellular mechanisms contributing to muscle
fatigue remain to be fully clarified (Bruton et al., 1998; Nagaraj
et al., 2000; de Paula Brotto et al., 2001; Brotto et al., 2002). A
better understanding of muscle weakness, atrophy and fatigue are
necessary to be able to develop medical interventions to restore
muscle strength and reduce the fatigability of muscles, which
are essential for effective treatment of muscle wasting disorders
(Romanick et al., 2013).
MUSCLE MYOPATHIES
A GENERAL DEFINITION
Myopathies are a distinct group of muscle wasting disorders.
Myopathies are neuromuscular disorders in which the main
symptom is muscle weakness caused by dysfunction of mus-
cle fibers (Chawla, 2011). There are many types of myopathies
including inherited myopathies such as muscular dystrophies
and acquired myopathies (Sewry, 2008). The distinct biochem-
ical and cellular mechanisms underlying the pathology of these
myopathies lead to greatly varied prognoses and treatments. Only
palliative care is currently available for many of these disorders
due to the limited understanding of their pathology.
THE SPECIAL CASE OF ETHANOL-INDUCED MYOPATHY
Ethanol-inducedmyopathy is acquired following excessive and/or
chronic consumption of alcohol and is roughly five times more
common than alcoholic cirrhosis (Estruch et al., 1993). Multiple
studies have confirmed the prevalence of this myopathy and
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determined that loss of muscle bulk as well as weakness is the
result. Abstinence and nutritional support facilitates recovery of
these patients but muscle strength does not revert to baseline val-
ues suggesting this is an irreversible process (Urbano-Marquez
and Fernandez-Sola, 2004). While the causative agent of this
myopathy has been known, the steps leading to its develop-
ment are unknown. Over the past 30 years progress has been
made in understanding of this disease entity. The mechanisms
underlying this multi-factorial disease include disruption of pro-
tein metabolism, signal transduction, and improper gene reg-
ulation (Urbano-Marquez and Fernandez-Sola, 2004; Noordzij
et al., 2007; Gonzalez-Reimers et al., 2010; Chawla, 2011). In vivo
and in vitro studies using models for alcohol-induced myopathy
observed a decrease in muscle mass specifically fast twitch (Type
II) fibers with multiple possible contributory mechanisms iden-
tified. Protein synthesis of myofibrillar proteins is impaired at
the initiation step of translation by alcohol (Preedy and Peters,
1988; Urbano-Marquez et al., 1995; Lang et al., 1999). Analysis
of mRNA and protein expression following chronic and acute
alcohol exposure determinedmultiple pathways and processes are
modified by alcohol including the ATP-dependent multi-catalytic
proteasome pathway. In skeletal muscles, alcohol induced apop-
tosis and changed expression and activity of the mTOR pathway
(Lang et al., 2003; Nakahara et al., 2003, 2006; Hong-Brown
et al., 2006). An additional contributory mechanism being evalu-
ated in this disease is oxidative damage due to increased reactive
oxygen species or changes in prevalence of antioxidants (Hofer
et al., 2005; Fernandez-Sola et al., 2007). Recently, corollary stud-
ies by Preedy et al. have firmly established that ethanol-induced
myopathies could account for more than 50% of all cases of
myopathies (Preedy et al., 2001a,b). Despite the prevalence of this
syndrome, effective treatments to either prevent or to cure this
condition remain unavailable.
MUSCULAR DYSTROPHY
Muscular dystrophies encompass another group of degenerative
myopathies which involve progressive muscle weakness that often
presents at birth or starting in early childhood However, there
are many types of muscular dystrophy that vary in their under-
lying genetic foundation, the severity of disease including the
body regions affected, the time of onset, and the rate of disease
progression. These distinct types are associated with perturba-
tions of various genes including DYSF (dysferlin), DUX4 (double
homeobox 4), LMN (Lamin), and the DMD gene that encodes
the dystrophin protein (Rahimov and Kunkel, 2013). Disruption
of these genes and several others lead to muscle damage par-
tially attributed to defects in sarcolemmal membrane stability and
repair. This damage is associated with progressive muscle weak-
ness, which appears to have a greater functional consequence than
loss of muscle mass.
Duchenne muscular dystrophy (DMD) is a recessive X-linked
form of muscular dystrophy that affects approximately 1 in 3600
boys. Symptoms of DMD tend to appear at or before six years
of age with muscle weakness in the legs and pelvis followed by
other body regions as the disorder progresses. Muscle deteriora-
tion and immobility eventually lead to paralysis with an average
lifespan of around 25 years. The observed muscle degeneration is
associated with mutations in the dystrophin gene. Dystrophin is
an important structural component of the dystroglycan complex
of the cell membrane that contributes to maintainingmuscle fiber
strength, preventing muscle injury, and retaining the mechani-
cal stability of muscle cells (Rahimov and Kunkel, 2013). Absence
of functional dystrophin protein leads to increased membrane
fragility, myocyte death, fibrosis, and progressive loss of muscle
strength. While more is known regarding the genetic pertur-
bations underlying DMD, available treatments to counteract or
prevent debilitating muscle weakness are still limited and lack
efficacy for this and other muscular dystrophies (Rahimov and
Kunkel, 2013).
CENTRONUCLEAR MUSCLE MYOPATHIES
Centronuclear myopathies (CNMs) are inherited neuromuscular
disorders with features of congenital myopathy that are charac-
terized by a high proportion of myofibers with centrally located
nuclei (Wallgren-Pettersson et al., 1995; Pierson et al., 2005; Tosch
et al., 2006). Normally, the nucleus is found along the edges of
rod-shaped muscle cells but in people with CNM the nucleus is
located in the center of these cells. It is unclear exactly how the
change in the location of the nucleus directly affects muscle cells.
It is likely that absence of the cellular mechanism responsible
for moving nuclei to the periphery, which could involve defects
in the cytoskeleton, is involved in the etiology of this myopathy
(Jungbluth et al., 2008). Centronuclear myopathies are divided
into forms based on their proposed pattern of inheritance, associ-
ated symptoms and muscle pathology. Mutations to the dynamin
2 gene (DNM2) were recently associated with the autosomal
dominant form of CNM while X-linked CNMs were associ-
ated with mutations in DNM2, AMPH (amphiphysin), MTM1
(myotubularin) and most recently MTMR14 (myotubularin-
related protein-14) genes (Laporte et al., 1996, 2003; Jungbluth
et al., 2008; Romero, 2010; Romero and Bitoun, 2011). How
mutations to these genes lead to the observed muscle weakness
and other specific features of these myopathies is unclear but it
is suggested that intracellular trafficking of essential molecules
is disrupted. The functional impact of the observed progres-
sive muscle weakness in CNMs is much greater than would be
expected if based simply on the loss of muscle mass leading to
interest in exploring other aspects of muscle physiology including
muscle strength and fatigue.
A LOOK AT KEY GENETIC PERTURBATIONS UNDERLYING MUSCLE
WASTING DISORDERS
Many genes have been proposed to be associated with various
muscle wasting disorders but the mechanisms by which these per-
turbations cause the observed pathology is complex and remains
unclear (Sewry, 2008). These proposed genes are involved in a
multitude of biochemical processes that are essential for proper
functioning of skeletal muscles including but not limited to
stabilizing cell membranes, Ca2+ handling required for proper
contraction and relaxation of muscles, and proper ubiquitin-
mediated degradation of proteins (Teixeira Vde et al., 2012).
While the loss of muscle mass is a critical part of these disorders,
ultimately it is the progressive muscle weakness that increases
the morbidity and mortality associated with musculoskeletal
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disorders. By understanding the biochemical processes leading
to the observed phenotypes, treatments and therapeutics can be
designed to reduce the functional impact of muscle weakness and
slow its progression.
Skeletal muscle serves many functions throughout the human
body beyond controlling muscle contraction including the
more recent focus on its role in body metabolism and in
metabolic and physical inactivity disorders. In this section, the
unique key functions of specific genes, including MTMR14,
SAR (sarcalumenin), MG29, and KLF15, will be discussed. Over
the past few years, these genes have provided novel insights
about muscle function in health and disease including muscle
fatigue, muscle metabolism, and muscle aging (see Figure 1).
These are major health issues as indicated by the large global
impact of musculoskeletal disorders on both morbidity and
mortality.
MTMR14 PLAYS A KEY ROLE IN CALCIUM HOMEOSTASIS
AND REGULATION OF AUTOPHAGY IN SKELETAL MUSCLE
CELLS
Myotubularin (MTM) and myotubularin-related (MTMR) genes
belong to a family of genes that encode dual-specificity phos-
phatases that modify phosphoinositides and regulate membrane
traffic (Dowling et al., 2009, 2010). Genes in this family are shown
to be important in muscle cell differentiation and mutations to
MTM and MTMR genes are observed in patients with specific
centronuclear myopathies (Laporte et al., 1996, 2003; Wishart
and Dixon, 2002; Dowling et al., 2009, 2010). In 2010, multiple
research groups identified mutations to MTMR14, one member
of this gene family, in several patients with CNMs and in sar-
copenia (Tosch et al., 2006; Dowling et al., 2009; Romero-Suarez
et al., 2010). The MTMR14 gene was first identified as a cytoplas-
mic localized phosphatase specific to skeletal and cardiac muscle
(Tosch et al., 2006; Vergne et al., 2009). Initially, this gene was
named as muscle-specific inositol phosphatase (MIP) or Jumpy
but when this gene was found to have high homology to the
catalytic motif of myotubularin family proteins, it was renamed
MTMR14 (Alonso et al., 2004; Tosch et al., 2006; Shen et al.,
2009). MTMR14 specifically targets 1-O-(3-sn-phosphatidyl)-
1D-myo-inositol 3-(dihydrogen phosphate) (phosphatidylinos-
itol 3-phosphate (PtdIns(3)P)) and L-alpha-phosphatidyl-D-
myo-inositol 3,5 bisphosphate, dipalmitoyl (phosphatidylinositol
3,5-diphosphate (PtdIns(3,5)P) substrates (Tosch et al., 2006;
Dowling et al., 2009; Gibbs et al., 2010; Romero-Suarez et al.,
2010). The products of this reaction are PtdIns and PtdIns(5)P,
which are involved in cytoskeletal dynamics and intracellular
membrane trafficking.
Using MTMR14 specific knockout mice, a number of research
groups explored the function of MTMR14 and identified
MTMR14 as a contributory factor in sarcopenia. Initial stud-
ies in these mice found excess PtdIns(3,5)P in skeletal muscle
cells confirming this as a substrate of MTMR14 and suggesting
this substrate plays an active role downstream (Shen et al., 2009;
Romero-Suarez et al., 2010). Altered abundance of this phospho-
inositide substrate and other phosphoinositides can cause defects
in Ca2+ homeostasis thus creating a possible link for MTMR14
function in skeletal muscle pathophysiology.
Brotto and collaborators observed young MTMR14 knockout
(KO) mice exhibited impaired Ca2+ homeostasis, decreased mus-
cle contractile force, and loss of muscle mass, all of which are
reminiscent of aging (Figure 1). In comparing muscles of young
and old wild type mice, levels of MTMR14 protein were reduced
in older wild type mice (Romero-Suarez et al., 2010). Similarly,
Shen et al. found mtmr14−/− mice were prone to greater skeletal
muscle fatigue and these mice showed decreased motor function
including decreased walking speed and decreased running time
prior to exhaustion. Extensor digitorum longus (EDL) muscles
of these knockout mice had a 60% decrease in force-generating
capacity and a prolonged relaxation profile post-muscle contrac-
tion compared to wild type mice of the same age. When the
fatigue-resistant, slow-twitch soleus muscles of these KO mice
were examined, they showed a shift toward higher frequencies
while exhibiting greater fatigue and diminished recovery post-
fatigue (Shen et al., 2009). This shift may reflect lesser Ca2+
release from the SR, therefore at higher frequencies of stim-
ulation more calcium can be released. These defects could be
explained by the alterations in calcium homeostasis, particularly
the reduced availability of calcium for effective calcium release
during contraction/relaxation cycles.
Knockout mice also exhibited defects in the regulation of Ca2+
levels including elevated resting Ca2+ concentrations, decreased
Ca2+ content in the sarcoplasmic reticulum (SR), and pro-
longed release or defective Ca2+ clearance in these muscles.
While store-operated calcium entry (SOCE) was functional in
these mutant muscles, it was severely blunted and associated
with muscle weakness and impairment of muscle relaxation.
The findings from MTMR14 knockout mice point to a role
of the MTMR14 phosphatase in regulating Ca2+ essential for
excitation-contraction coupling and SOCE function. Defects in
these processes result in muscle fibers that are more suscepti-
ble to exercise-induced muscle damage and will lead to muscle
weakness, both of which are trademarks of muscle wasting espe-
cially in sarcopenia (Zhao et al., 2008; Romero-Suarez et al.,
2010) (Figure 1). For example, elevated levels of Ca2+ can lead to
activation of proteolytic enzymes and dysfunctional autophagy.
Dowling et al. (2010) determined that while MTMR14 is required
for motor function, it is not essential for myocyte homeosta-
sis or normal embryonic development. Morpholino-mediated
knockdown of MTMR14 in zebrafish resulted in morphological
abnormalities and a developmental motor phenotype charac-
terized by diminished spontaneous contractions and impaired
excitation-contraction coupling. Unlike knockdown of another
member of this gene family, MTM1, in this model, knockdown
of MTMR14 did not affect muscle ultrastructure (Shen et al.,
2009). MTMR14 appeared to act in concert with MTM1 in the
development ofmuscle pathology since simultaneous knockdown
of both genes impaired motor function and muscle ultrastruc-
ture (Dowling et al., 2009). The resulting phenotype was more
severe than that observed with knockdown of either gene alone.
Analysis following the knockdown of both of these genes sug-
gested the phenotype observed is likely mediated by an increase
in autophagy (Dowling et al., 2010). Defects in Ca2+ homeostasis
observed inmtmr14−/− mice may be an initiator of this observed
autophagy.
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FIGURE 1 | Schematic drawing of the triad junction, the chief site of the
E-C coupling process in skeletal muscles. The predicted localization of the
four genes/proteins emphasized in this review article is shown and they are
represented in different colors along with the Dihydropyridine Receptor
(DHPR), the Ryanodine Receptor type 1 (RyR1) and Calsequestrin (CSQ). In
young muscles E-C coupling is effectively maintained through coordinated
actions of the E-C coupling machinery and the optimal participation of MG29,
MTMR14, SAR, and KLF15. Their concentration and/or effectiveness is
reduced with aging, which associates with structural changes of the triad
junction itself. Together these biochemical and morphological changes
contribute to the reduced coupling between depolarization of the sarcolemma
and contraction due to the reduced calcium release capacity of aged muscles.
In summary, “E-C coupling quality” is reduced in aged muscles, and becomes
a key factor to reduced muscle quality during aging. The steps of the E-C
coupling process are described in detail in the text. In skeletal muscles,
depolarization of the sarcolemma and its invaginations (t-tubules) represented
by the lightning bolt in yellow color alters the configuration of the DHPR,
which modifies its interaction with RyR1, leading to the dominant type of
calcium release in skeletal muscle (depolarization-induced calcium release,
DICR). This initial release phase can be further amplified by a secondary
mechanism, calcium-induced calcium release (CICR), the main release
mechanism in cardiac muscles. The structural deformation as well as the lack
of organized triads is a hallmark of aged muscles and also common in other
diseases covered in this article. Not detailed in this figure is the process of
calcium entry or re-entry, store-operated calcium entry (SOCE), responsible
for continual refilling of the sarcoplasmic reticulum (SR). SOCE is also reduced
with aging, which we have postulated contributes to sarcopenia and to the
un-matching between muscle mass and muscle contractile force during
aging, since force/power decrease significantly more than the observed
decrease in muscle mass. We foresee that new generations of drugs could be
developed to specifically target the different steps of E-C coupling in disease
states to increase efficiency of Ca2+ handling.
The role of MTMR14 as a negative regulator of autophagy
was further evaluated by Gibbs et al. who observed several muta-
tions in the MTMR14 gene in cases of CNM (Gibbs et al., 2010).
In these studies, knockdown of MTMR14 in vitro and in vivo
significantly changed muscle function especially in embryos
where decreased developmental motor activity and pronounced
fatigability were observed. Knockdown also increased basal and
starvation-induced autophagy of muscle cells demonstrated by
increased LC3-II levels (Vergne et al., 2009; Dowling et al., 2010).
During autophagy, the cytoplasmic form of LC3 (LC3-I) is pro-
cessed to create LC3-II, which is recruited to autophagosomes.
This conversion is used tomonitor autophagic activity and LC3-II
is considered an autophagic marker. A possibility that MTMR14
may act as a modifier of disease rather than direct cause has been
raised. While function-altering MTMR14 mutations have been
found in sporadic cases of centronuclear myopathy, one of these
patients also carried a disease-associated mutation in DNM2. A
more severe phenotype was observed in this patient than patients
with only the DNM2 mutation suggesting MTMR14 was not the
primary cause of disease but did have a role in exacerbating the
phenotype (Bitoun et al., 2005; Dowling et al., 2010).
The mutation ofMTMR14 in cases of CNM and the decreased
presence of MTMR14 protein in muscles from aged mice
suggest the importance of MTMR14 in muscle physiology and
pathophysiology. MTMR14 studies have identified its roles in reg-
ulating the abundance of phosphatidylinositol phosphates, which
observably alters Ca2+ homeostasis. Changes in Ca2+ concentra-
tions are a known inducer of autophagy supporting the increased
levels of autophagy observed following MTMR14 knockdown
(Bonaldo and Sandri, 2013; Smaili et al., 2013). Functionally,
MTMR14 affectedmuscle performance specificallymuscle fatigue
and muscle weakness.
One key message from these MTMR14 studies is that finely
controlled levels of phosphoinositides in muscle cells is essential
for maintaining Ca2+ homeostasis and enabling effective mus-
cle performance. Improper regulation of Ca2+ concentrations by
any means, including that observed with these MTMR14 stud-
ies, interferes with excitation-contraction (E-C) coupling, which
is another physiological process fundamental to muscle pathol-
ogy. E-C coupling, the conversion of an electrical stimulus by
cells to a mechanical response, is aberrantly regulated in various
pathologies including muscle wasting disorders (Yoshida et al.,
2005; Rossi and Dirksen, 2006). In skeletal muscle, E-C coupling
requires two specific proteins, the sarcoplasmic reticulum Ca2+
release channel (known as the ryandonine receptor or RyR) and
voltage-gated Ca2+ channels (known as dihydropyridine recep-
tors or DHPRs). Depolarization of the membrane potential of
these cells by an action potential activates voltage-gated DHPRs.
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This activates RyR type 1 via physical linkage and conforma-
tional changes. As RyRs open, Ca2+ is released from the SR
into the junctional space then diffuses into the cytoplasm to
cause a Ca2+ transient (Bellinger et al., 2008; Andersson et al.,
2011). Ca2+ released into the cytoplasm binds to Troponin C
on actin filaments to produce force or contraction of the cell.
The sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pumps
Ca2+ back into the SR and with this the force begins to decline
and relaxation occurs. The SR is the dynamic Ca2+ governor in
muscle cells that receives feedback allowing it to maintain SR
and cytoplasmic Ca2+ levels. The SR contains an elaborate set of
Ca2+ regulating proteins including luminal Ca2+ binding pro-
teins involved in Ca2+ storage, SR Ca2+ release channels, and
SERCA pumps for Ca2+ reuptake. Spatial and temporal control
of Ca2+ uptake, Ca2+ buffering, and Ca2+ release is maintained
by these highly organized Ca2+ regulatory proteins in the SR
(O’Connell et al., 2008) (Figure 1).
SARCALUMENIN FUNCTIONS IN CALCIUM HANDLING
Another gene related to E-C coupling with a role in muscle
pathology is sarcalumenin (SAR). Similar to calsequestrin, sar-
calumenin is a Ca2+ binding protein localized to the sarcoplasmic
reticulum of the intracellular Ca2+ store of striated muscle cells.
While calsequestrin and sarcalumenin are both Ca2+ binding
proteins of the SR, they are located in different regions of the
SR. Sarcalumenin observably colocalizes with SERCA. Two iso-
forms of SAR, a 160 kDa and a 35 kDa glycoprotein are formed
as the products of alternative splicing of the primary transcript
(Leberer et al., 1989, 1990). The SAR luminal protein binds
Ca2+ with high capacity but low affinity (Zhao et al., 2005).
Increased SAR expression during muscle development suggests
its role in proper functioning of mature SR (Yoshida et al.,
2005). Currently, sarcalumenin is considered to be important
in the release and uptake of Ca2+, which is the essential sec-
ond messenger of the excitation-contraction-relaxation cycle in
skeletal muscle cells (Yoshida et al., 2005; Rossi and Dirksen,
2006; O’Connell et al., 2008). Using a SAR knockout mouse,
Yoshida et al. determined that while SAR is not essential for
fundamental muscle function, it does play a role in improving
Ca2+ handling functions of the SR in striated muscle. Muscle
from sar−/− mice exhibited weakened Ca2+ uptake in isolated
SR vesicles. In mutant muscles, expression of SERCA protein
was decreased while levels of the mRNA remained consistent
with wild type muscles. Sarcalumenin unlike most proteins of
the SR lacks the four amino acid (KDEL) ER/SR retention sig-
nal so it is likely that the direct interaction of SAR with SERCA
serves this function (Leberer et al., 1990; Yoshida et al., 2005;
Dowling et al., 2009). This is suggestive of SAR acting as a chap-
erone of SERCA and its involvement in SERCA turnover since the
absence of SAR directly impacts the abundance of SERCA protein.
Together these findings suggest SAR contributes to Ca2+ buffer-
ing and the maintenance of Ca2+ pump proteins, both of which
are essential for E-C coupling and retaining muscle strength.
From current research, it remains inconclusive whether SERCA
content or a combination of SERCA content and buffering capac-
ity is responsible for the observed effects linked to sarcalumenin
expression.
Reduced levels of SAR protein were detected in the dystrophin
deficient mdx mouse model of muscular dystrophy leading Zhao
et al. to further evaluate its role in muscle wasting (Dowling
et al., 2004; Zhao et al., 2005). The sar−/− mouse model exhib-
ited enhanced fatigue resistance. This finding was determined
by evaluating the Ca2+ ion storage function of the contrac-
tile machinery using single, mechanically skinned muscle fibers
loaded with two calcium dyes, one that specifically reported
t-tubule calcium and the other that reported SR calcium (Zhao
et al., 2005). A number of key findings were obtained using this
method for comparison of wild type and sar−/− mice. Muscle
fibers from SAR deficient mice showed elevated SOCE activity as
previously observed and reduced fatigability. Putting the findings
from these studies together suggests the fatigue resistant pheno-
type of sar−/− mice is likely due to more effective E-C coupling
and SOCE observed in these muscles.
While ATP is thought to play a major role in fatigue, it is
typically associated with long-term fatigue under specific con-
ditions. It has been demonstrated by many laboratories that a
major culprit in the muscle fatigue process is dysfunctional intra-
cellular calcium homeostasis, specifically impaired Ca2+ release
from the SR. In normal muscles, calcium stores are more eas-
ily depleted than ATP stores and normal muscle function is
directly related to Ca2+ availability. As less Ca2+ becomes avail-
able with each contraction/relaxation cycle, fatigue will develop
if SOCE is reduced (Brotto et al., 2002; Weisleder et al., 2006;
Allen et al., 2008; Place et al., 2009). The studies discussed here
concluded the role of sarcalumenin in SOCE function may be
useful in reducing or reversing weakness associated with vari-
ous muscle wasting disorders. Additionally, these studies raised
the possibility that the reduced levels of SAR protein observed in
mdx mice could be interpreted as a compensatory mechanism of
adaptation in muscles from these mice in an effort to improve
muscle function (Zhao et al., 2005). Further studies suggested that
another geneMitsugumin-29 (MG29), might be involved with the
compensation observed in the sar−/− muscle.
MG29 FUNCTIONS IN MUSCLE FATIGUE AND
STORE-OPERATED CALCIUM ENTRY
MG29 is another protein of interest for its identified role in mus-
cle physiology and pathology. Over the last ten years, research
has evaluated the role of MG29 in muscle fatigue and SOCE.
Using an extensive proteoimmunologic library of antibodies that
targeted proteins of the triad junctional membrane structures
of skeletal muscle, MG29 was one of the most significant pro-
teins identified (Takeshima et al., 1998). Mitsugumin-29 (MG29)
is a member of the synaptophysin family of transmembrane
proteins that has been extensively evaluated for their role in mus-
cles. MG29 is almost exclusively expressed in skeletal muscle
fibers (Takeshima et al., 1998). MG29 contains four transmem-
brane domains with a cytoplasmic amino and carboxy terminus.
The transmembrane domains allow MG29 to localize at both
the transverse (t-) tubular membrane and the SR membrane
of the triad junction, which suggests a possible role of MG29
in mediating communication between t-tubular and junctional
SR membranes (Thomas et al., 1988, 1998; Thomas and Betz,
1990).
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Besides the homologous amino acid sequence, MG29 also
shares other characteristic structural features with members of
the synaptophysin family of neurotransmitters. Synaptophysin
was identified as an abundant immunogenic membrane protein
of small synaptic vesicles and is also found in neurosecretory
granules (Thomas et al., 1988, 1998; Thomas and Betz, 1990).
The structural role of synaptophysin in synaptic vesicle biogen-
esis and its tight interaction with other proteins of the synaptic
vesicle membrane contribute to its essential role in neurotrans-
mitter secretion (Thiele et al., 2000). Similarities between the
structure and localization patterns of MG29 to synaptophysin
suggest MG29 has an important role in modulating membrane
structures in skeletal muscle. Skeletal muscle is one of the most
plastic tissues in the human body and since normal muscle
physiology requires the formation and maintenance of complex
membrane structures, it has been proposed that MG29 may be
the structural counterpart of synaptophysin in skeletal muscle
biogenesis and maintenance (Booth et al., 2000; Booth and Vyas,
2001).
Mutations ofMG29 have not been observed in specific skeletal
muscle wasting disorders; however, its expression and abundance
are observed to vary under certain conditions. For example,
MG29 expression is known to decrease in aging mouse skeletal
muscle (Weisleder et al., 2006). To determine the physiological
role of MG29 in normal muscle function and possibly in mus-
cle pathology, an MG29 knockout mouse was established. The
MG29 null mouse was the first experimental indication of the role
MG29 plays in muscle membrane integrity. Skeletal muscle from
thesemice showedmultiple abnormalities inmembrane structure
specifically around the triad junction. Within the triad junction,
t-tubules appeared swollen and the SR networks were poorly
formed with fragmented structures (Nishi et al., 1999; Thiele
et al., 2000). Based on what is known regarding synaptophysin,
these findings suggest MG29 functions in membrane fusion asso-
ciated with the creation andmaintenance of membrane structures
in the triad junction.
Considering the extent of malformation of the triad junc-
tion membrane ultrastructure, the lack of a functional impact
of MG29 knockout was surprising so the phenotype was fur-
ther evaluated under conditions of physiological stress (Nagaraj
et al., 2000). During treadmill running, MG29 knockout mice
ran significantly less and were unable to sustain physical activity
for the extended period of time compared to littermate con-
trols suggesting a direct role of MG29 in muscle performance
specifically during increased physical activity. Additional ex vivo
muscle contractility assays confirmed increased fatigability in iso-
lated mg29−/− muscles. MG29 null muscles fatigued to a greater
extent while also recovering less after fatigue. These muscles also
produced less force than wild type control mice even with the
addition of caffeine. These findings continue to suggest that E-C
coupling inMG29 ablated skeletal muscles is disrupted sincemus-
cle fatigue was reduced in mg29−/− muscles when Ca2+ was
removed from the extracellular medium and by pharmacologi-
cally blocking extracellular Ca2+ entry (Nagaraj et al., 2000). It
is clear that the inability of humans to sustain physical activ-
ity may lead to chronic degenerative diseases, reduced muscle
function, and muscle wasting (Booth et al., 2000). However,
the contribution of changes in fatigability to sarcopenia and age
related frailty has not been fully resolved as some reports indi-
cate some degree of fatigue resistance develops during muscle
aging (Gonzalez and Delbono, 2001a,b). Given that MG29 levels
decrease in aging skeletal muscle these findings show that mus-
cle aging is a multivariate situation where changes in multiple
factors contribute to the development of aging phenotypes, and
emphasize the need for additional studies in this important area
of investigation (Weisleder et al., 2006).
The implication of extracellular Ca2+ entry as a major fac-
tor in muscle fatigue in mg29−/− muscle lead to investigation
of whether store-operated calcium entry (SOCE) is altered in
these muscles compared to wild type control muscles. SOCE is an
extracellular calcium entry pathway. In SOCE, reduced Ca2+ con-
centration in the intracellular stores of the sarcoplasmic reticulum
induces influx of Ca2+ from the extracellular space to replenish
the diminished Ca2+ stores. While SOCE functions in many dif-
ferent cell types, it is extremely important in the physiology of
excitable cells such as muscles and neurons (Albert and Large,
2003;Ma and Pan, 2003; Nilius, 2004; Targos et al., 2005;Ma et al.,
2006; Lewis, 2007). Disruption of SOCE activity results in various
physiological pathologies (Nilius, 2004; Targos et al., 2005). Its
impairment can lead to numerous disorders including cancer and
primary immunodeficiency and is being continually researched
for its possible role in Alzheimer disease and age-related muscle
weakness (sarcopenia) (Nilius, 2004; Targos et al., 2005; Lewis,
2007). The diverse pathologies linked to SOCE is likely due to the
wide ranging importance of Ca2+ as a second messenger in con-
trolling cellular functions including contraction, secretion, gene
expression, and cell cycle.
SOCE is important in long term maintenance of Ca2+ home-
ostasis since it is the mechanism by which additional Ca2+ is
provided for muscle contraction under conditions where SR Ca2+
is depleted such as fatigue, intense exercise, and some patholo-
gies (Zhu and Birnbaumer, 1998; Elliott, 2001; Putney et al.,
2001; Parekh and Putney, 2005; Yoshida et al., 2005; Zhao et al.,
2005, 2008). Elevated SOCE can also be detrimental as increased
resting intracellular Ca2+ concentrations potentially underlies
development and progression of the muscle injury observed with
muscular dystrophy (Brotto et al., 2002). Together, these differ-
ential effects of aberrant SOCE suggest its fine-tuned modulation
is essential for overall skeletal muscle health. Reduced SOCE was
displayed in MG29 null muscles supporting a role of Ca2+ entry
in the observed phenotypic changes (Pan et al., 2002). mg29−/−
muscles fatigued to a greater extent when blockers of SOCE were
employed which suggests that the main problem in Ca2+ han-
dling is due to reduced SOCE leading to reduced SR calcium
storage. Additional studies using more specific SOCE antagonists
and genetically silencing players in SOCE will shed more light on
this mechanism. Aberrant reduction of SOCE was mirrored in
aged skeletal muscles, which also demonstrated decreased expres-
sion of MG29 protein resulting in a direct correlation of MG29
protein levels and fatiguing of skeletal muscles.
Additional evidence to support the role of MG29 in SOCE and
muscle fatigue stems from the sarcalumenin knockoutmouse pre-
viously discussed (Yoshida et al., 2005). Muscles isolated from
sar−/− mice exhibited reduced fatigability and elevated SOCE
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activity compared to wild type mice. These observed features cor-
related with increased abundance of MG29 (Zhao et al., 2005).
Based on the increased susceptibility of MG29 null muscles to
fatigue, it is proposed that the increased presence of MG29 in
sar−/− mice may be compensatory for the loss of SAR. The com-
pensatory mechanismwould contribute to enhanced Ca2+ release
from the SR andmore efficient SR coupling in these muscles. This
finding further supports the role of bothMG29 and sarcalumenin
in maintenance of Ca2+ homeostasis and suggests both genes as
targets for restoring muscle strength. Putting all these findings
together, MG29may function as a sentinel against age related dys-
function in skeletal muscle by its likely role in regulation of SOCE.
MG29 and SAR may serve as therapeutic targets for pathophys-
iologic muscle conditions including aging and dystrophy where
muscle fatigue and strength are impacted. The two main physio-
logic effects on skeletal muscle bymuscle wasting disorders are the
physical loss of muscle mass and increased muscle weakness. Both
are important processes in the effort to maintain proper func-
tioning of skeletal muscles especially with age. The genes covered
above, MTMR14, SAR, and MG29, are being heavily researched
for their role in muscle weakness and the induction of fatigue in
these disorders. On the other hand, KLF15 has been evaluated for
its role in the loss of muscle mass and its possible role in muscle
weakness.
KRUPPEL-LIKE FACTOR 15
Kruppel-Like Factor 15 (KLF15) belongs to the Kruppel-like fac-
tor (KLF) family of transcription factors in a zinc-finger class of
DNA binding transcriptional factors. Their transcriptional activ-
ity makes their function critical in muscle physiology and muscle
pathophysiology. KLFs include three Cys2/His2 containing zinc
fingers, all of which are located at the extreme c-terminus of the
protein. The seven residues separating these zinc fingers are also
highly conserved but the non-DNA binding regions of these fac-
tors are highly divergent allowing modulation of transactivation
or transrepression and mediating protein-protein interactions
(Bieker, 1996; Turner and Crossley, 1999; Haldar et al., 2007,
2012; Pearson et al., 2008) This sequence variation likely con-
tributes to the varied expression patterns and functions of the
familymembers. KLFs are differentially expressed in development
as well as in response to physiological stresses and are found to
play critical roles in cardiovascular biology and in muscle biology,
including skeletal muscle (Yamamoto et al., 2004; Haldar et al.,
2007). Of specific interest in skeletal muscle biology is KLF15.
KLF15 is expressed in all three types of muscle and is known to be
a negative regulator of hypertrophic remodeling within the heart
by repressing key features required for the hypertrophic process
(Fisch et al., 2007; Haldar et al., 2007, 2012).
Research over the past ten years has discovered the impor-
tance of KLF15 in skeletal muscle metabolism for both amino
acid catabolism and lipid utilization. Its role in metabolism may
contribute to its association with muscle atrophy. In two separate
studies, KLF15 was evaluated for its function in muscle atrophy
and hypertrophy. Schakman et al. researched KLF15 expression
in response to glucocorticoids (GC). Long term administration of
glucocorticoids as treatment for specific diseases results in debil-
itating muscle atrophy (Schakman et al., 2013). Biochemically,
glucocorticoids were found to increase the rate of protein break-
down and decrease the rate of protein synthesis thus contributing
to a loss of muscle mass (Tomas et al., 1979; Goldberg et al.,
1980; Lofberg et al., 2002; Drummond and Rasmussen, 2008;
Schakman et al., 2013). It was determined thatmTORC1 signaling
is repressed in the presence of increased GCs through enhanced
transcription of REDD1 and KLF15. The mechanism by which
KLF15 contributes to protein catabolism is not completely under-
stood but KLF15 appears to activate branched-chain amino acid
aminotransferases (BCAT) that are responsible for the degrada-
tion of branched chain amino acids (BCAAs). Accelerated BCAA
degradation leads to the observed decrease in mTORC1 activity
(Chaillou et al., 1985; Bodine et al., 2001; Shimizu et al., 2011;
Atherton and Smith, 2012). Further analysis showed that KLF15
in coordination with FOXO1 upregulates E3 ubiquitin ligases
Atrogin-1 and MURF1 (Schakman et al., 2013). KLF15 appears
to contribute to muscle atrophy by altering the ratio of protein
catabolism and synthesis.
While studying the development of muscle hypertrophy,
Chaillou et al. recently discovered that KLF15 expression is
downregulated in response to overload induced hypertrophy.
Decreased KLF15 expression in skeletal muscle resulted in greater
protein accretion possibly through decreased degradation of
BCAAs leading to increased availability of BCAAs andmaintained
synthesis of proteins (Chaillou et al., 1985). The mechanism by
which KLF15 affects protein synthesis through altered BCAA
degradation remains unclear due to the complex nature of this
process. Protein synthesis depends on specific roles of the liver
and constant crosstalk between the liver and skeletal muscles as
well as the commonly ignored function of insulin, which also
stimulates skeletal muscle utilization of amino acids/proteins,
besides its more readily, attributed effect on glucose uptake. In
a parallel study, increased concentrations of BCAAs prolonged
activation of mTORC1, which is vital to the process of mus-
cle hypertrophy by enhancing protein synthesis. For this reason,
KLF15 may be a target of future studies for controlling skele-
tal muscle hypertrophy and more specifically skeletal muscle
atrophy associated with certain conditions. It appears repression
of KLF15 may beneficially impact skeletal muscle by restoring
muscle cell loss.
While the role of KLF15 in protein synthesis and catabolism
has been researched, KLF15 has also been shown to have a role in
lipid utilization in skeletal muscles. With its regulation of amino
acid catabolism and its role in fasting gluconeogenesis, KLF15 is
proposed to have a role in metabolic adaptation in conditions of
physiologic stress such as endurance exercise and fasting (Gray
et al., 2007; Shimizu et al., 2011; Haldar et al., 2012). In the
lack of sufficient glucose, which is vital for brain function, skele-
tal muscle resorts to proteins and lipids for its fuel. Specifically,
abnormalities of lipid flux impact energetic failure and tolerance
to exercise. Studies by Haldar et al. propose that KLF15 and its
signaling interaction with glucocorticoids are important in the
physiological response to exercise based on its role in both pro-
tein and lipid metabolism (Haldar et al., 2012). Yamamoto et al.
observed that fasting elevated levels of KLF15 and this lead to
increased expression of the mitochondrial acetyl-CoA synthetase
gene AceCS2 in skeletal muscle (Fujino et al., 2001; Yamamoto
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et al., 2004). This enzyme is vital during periods of insufficient
glucose and under ketogenic conditions for providing an energy
source for muscles (Yamamoto et al., 2004; Gray et al., 2007).
The exact role of KLF15 in metabolic lipid flux in skeletal mus-
cle remains unknown but research is focused on understanding
the role of KLF15 in defective lipid flux and protein catabolism,
both of which can contribute to detrimental changes in muscle
cells. Atrophy can be a result of these defects as muscles try to
adapt to metabolic changes. In addition to its evaluation in atro-
phy, KLF15 has been linked to facioscapulohumeral dystrophy
(FSHD). For FSHD, KLF15 activated the D4Z4 enhancer element
leading to overexpression of DUX4 while this effect was abolished
with silencing of KLF15. DUX4 is known to be overexpressed in
this type of muscular dystrophy (Dmitriev et al., 2011). KLF15
appears to be a promising research target in understanding how
metabolism of proteins and lipids may contribute to muscle atro-
phy as well as its possible role in muscle wasting disorders such as
types of muscular dystrophy (Chaillou et al., 1985).
CONCLUSIONS AND FUTURE DIRECTIONS
The available research on MTMR14, sarcalumenin, MG29, and
KLF15 in skeletal muscle biology has provided new information
toward the better understanding of muscle physiology and patho-
physiology. Specific interest is focused on these genes and their
possible roles in muscle weakness including that observed during
the natural aging process (Figure 1). In aging, the most debilitat-
ing effects of sarcopenia are the increased muscle weakness and
fatigue. This is the case for many other muscle wasting disor-
ders. Muscle wasting disorders display a loss of muscle mass but of
greater functional importance is the increased muscle weakness.
Muscle weakness is the pathophysiological condition that has the
greatest effect on quality of life, independence, and outcome for
individuals affected by these disorders. The genes reviewed here
are observed to affect key processes in muscle function includ-
ing SOCE and E-C coupling, which both have proposed roles in
muscle fatigue and weakness. While the underlying mechanisms
behind these genes and other genes in the loss of muscle strength
are finally coming to light, hope is that with additional research,
these genes will provide new avenues in finding a therapeutic tar-
get in the fight against muscle wasting disorders. We foresee that a
new generation of drugs that specifically modulate E-C coupling
and calcium homeostasis would be great assets in this fight that is
currently being won by the diseases.
AUTHOR CONTRIBUTIONS
Dr. Manring drafted and organized the entire review. Drs.
Weisleder and Brotto have had substantial contributions to the
conception or design of the work, the acquisition, analysis, and
interpretation of data on the genes presented in this review. Dr.
Leticia Brotto has contributed during more than one decade in
conducting a large amount of the many experiments that led to
characterization of the knockout animal models discussed in this
article. Dr. Abreu critically revised the initial draft for intellectual
and organization content. Dr. Brotto conducted the final approval
of the version to be published in agreement with all the authors
and he is accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the
work are appropriately investigated and resolved.
ACKNOWLEDGMENTS
The work summarized in this review article was partially
supported by NIH-National Cancer Institute TREC Award
U54-116867, American Heart Association Grant (N5505355),
NIH-National Institutes of Aging Program Project Grant P01
AG039355-01-A1 and the Thompson Endowment Fund (Marco
Brotto). In addition, the work was support by the NIH-NIAMS
grant R01AR063084 to Dr. NoahWeisleder and by a NIHTraining
Grant T32 (T32HL098039) Fellowship.
REFERENCES
Albert, A. P., and Large, W. A. (2003). Store-operated Ca2+-permeable non-
selective cation channels in smooth muscle cells. Cell Calcium 33, 345–356. doi:
10.1016/S0143-4160(03)00048-4
Allen, D. G., Lamb, G. D., and Westerblad, H. (2008). Skeletal muscle fatigue: cel-
lular mechanisms. Physiol. Rev. 88, 287–332. doi: 10.1152/physrev.00015.2007
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Osterman, A., Godzik, A., et al.
(2004). Protein tyrosine phosphatases in the human genome. Cell 117, 699–711.
doi: 10.1016/j.cell.2004.05.018
Andersson, D. C., Betzenhauser, M. J., Reiken, S., Meli, A. C., Umanskaya, A.,
Xie, W., et al. (2011). Ryanodine receptor oxidation causes intracellular cal-
cium leak and muscle weakness in aging. Cell Metab. 14, 196–207. doi:
10.1016/j.cmet.2011.05.014
Atherton, P. J., and Smith, K. (2012). Muscle protein synthesis in response to
nutrition and exercise. J. Physiol. 590(Pt 5), 1049–1057. doi: 10.1113/jphys-
iol.2011.225003
Bellinger, A. M., Reiken, S., Dura, M., Murphy, P. W., Deng, S. X., Landry, D. W.,
et al. (2008). Remodeling of ryanodine receptor complex causes “leaky” chan-
nels: a molecular mechanism for decreased exercise capacity. Proc. Natl. Acad.
Sci. U.S.A. 105, 2198–2202. doi: 10.1073/pnas.0711074105
Bieker, J. J. (1996). Isolation, genomic structure, and expression of human
erythroid Kruppel-like factor (EKLF). DNA Cell Biol. 15, 347–352. doi:
10.1089/dna.1996.15.347
Bitoun, M., Maugenre, S., Jeannet, P. Y., Lacene, E., Ferrer, X., Laforet, P., et al.
(2005). Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat.
Genet. 37, 1207–1209. doi: 10.1038/ng1657
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R.,
et al. (2001). Akt/mTOR pathway is a crucial regulator of skeletal muscle hyper-
trophy and can prevent muscle atrophy in vivo.Nat. Cell Biol. 3, 1014–1019. doi:
10.1038/ncb1101-1014
Bonaldo, P., and Sandri, M. (2013). Cellular and molecular mechanisms of muscle
atrophy. Dis. Model. Mech. 6, 25–39. doi: 10.1242/dmm.010389
Booth, F. W., Gordon, S. E., Carlson, C. J., and Hamilton, M. T. (2000). Waging
war on modern chronic diseases: primary prevention through exercise biology.
J. Appl. Physiol. 88, 774–787.
Booth, F. W., and Vyas, D. R. (2001). Genes, environment, and exercise. Adv. Exp.
Med. Biol. 502, 13–20. doi: 10.1007/978-1-4757-3401-0_3
Bortz, W. M. T., and Bortz, W. M. 2nd. (1996). How fast do we age? Exercise
performance over time as a biomarker. J. Gerontol. A Biol. Sci. Med. Sci. 51,
M223–M225. doi: 10.1093/gerona/51A.5.M223
Brooks, S. V., and Faulkner, J. A. (1994). Skeletal muscle weakness in old age: under-
lying mechanisms. Med. Sci. Sports Exerc. 26, 432–439. doi: 10.1249/00005768-
199404000-00006
Brotto, M., and Abreu, E. L. (2012). Sarcopenia: pharmacology of today and
tomorrow. J. Pharmacol. Exp. Ther. 343, 540–546. doi: 10.1124/jpet.112.191759
Brotto, M. A., Nosek, T. M., and Kolbeck, R. C. (2002). Influence of ageing on the
fatigability of isolated mouse skeletal muscles from mature and aged mice. Exp.
Physiol. 87, 77–82. doi: 10.1113/eph8702224
Bruton, J. D., Lannergren, J., and Westerblad, H. (1998). Mechanisms underlying
the slow recovery of force after fatigue: importance of intracellular calcium. Acta
Physiol. Scand. 162, 285–293. doi: 10.1046/j.1365-201X.1998.0292f.x
Chaillou, T., Lee, J. D., England, J. H., Esser, K. A., and McCarthy, J. J. (1985). Time
course of gene expression during mouse skeletal muscle hypertrophy. J. Appl.
Physiol. 115, 1065–1074. doi: 10.1152/japplphysiol.00611.2013
Chawla, J. (2011). Stepwise approach to myopathy in systemic disease. Front.
Neurol. 2:49. doi: 10.3389/fneur.2011.00049
de Paula Brotto, M., van Leyen, S. A., Brotto, L. S., Jin, J. P., Nosek, C. M., and
Nosek, T. M. (2001). Hypoxia/fatigue-induced degradation of troponin I and
www.frontiersin.org February 2014 | Volume 5 | Article 37 | 9
Manring et al. ECC genes in muscle weakness
troponin C: new insights into physiologic muscle fatigue. Pflugers Arch. 442,
738–744. doi: 10.1007/s004240100587
Dmitriev, P., Petrov, A., Ansseau, E., Stankevicins, L., Charron, S., Kim, E.,
et al. (2011). The Kruppel-like factor 15 as a molecular link between myo-
genic factors and a chromosome 4q transcriptional enhancer implicated
in facioscapulohumeral dystrophy. J. Biol. Chem. 286, 44620–44631. doi:
10.1074/jbc.M111.254052
Dowling, J. J., Low, S. E., Busta, A. S., and Feldman, E. L. (2010). Zebrafish
MTMR14 is required for excitation-contraction coupling, developmental motor
function and the regulation of autophagy.Hum.Mol. Genet. 19, 2668–2681. doi:
10.1093/hmg/ddq153
Dowling, J. J., Vreede, A. P., Low, S. E., Gibbs, E. M., Kuwada, J. Y., Bonnemann, C.
G., et al. (2009). Loss of myotubularin function results in T-tubule disorgani-
zation in zebrafish and human myotubular myopathy. PLoS Genet. 5:e1000372.
doi: 10.1371/journal.pgen.1000372
Dowling, P., Doran, P., and Ohlendieck, K. (2004). Drastic reduction of sar-
calumenin in Dp427 (dystrophin of 427 kDa)-deficient fibres indicates that
abnormal calcium handling plays a key role in muscular dystrophy. Biochem.
J. 379, 479–488. doi: 10.1042/BJ20031311
Drummond, M. J., and Rasmussen, B. B. (2008). Leucine-enriched nutrients and
the regulation of mammalian target of rapamycin signalling and human skeletal
muscle protein synthesis. Curr. Opin. Clin. Nutr. Metab. Care 11, 222–226. doi:
10.1097/MCO.0b013e3282fa17fb
Elliott, A. C. (2001). Recent developments in non-excitable cell calcium entry. Cell
Calcium 30, 73–93. doi: 10.1054/ceca.2001.0215
Estruch, R., Nicolas, J. M., Villegas, E., Junque, A., and Urbano-Marquez, A.
(1993). Relationship between ethanol-related diseases and nutritional status in
chronically alcoholic men. Alcohol Alcohol. 28, 543–550.
Faulkner, J. A., Brooks, S. V., and Zerba, E. (1995). Muscle atrophy and weak-
ness with aging: contraction-induced injury as an underlying mechanism.
J. Gerontol. A Biol. Sci. Med. Sci. 50(Spec No), 124–129.
Fernandez-Sola, J., Preedy, V. R., Lang, C. H., Gonzalez-Reimers, E., Arno, M.,
Lin, J. C., et al. (2007). Molecular and cellular events in alcohol-induced
muscle disease. Alcohol. Clin. Exp. Res. 31, 1953–1962. doi: 10.1111/j.1530-
0277.2007.00530.x
Fisch, S., Gray, S., Heymans, S., Haldar, S. M., Wang, B., Pfister, O., et al. (2007).
Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy. Proc. Natl.
Acad. Sci. U.S.A. 104, 7074–7079. doi: 10.1073/pnas.0701981104
Fujino, T., Kondo, J., Ishikawa, M., Morikawa, K., and Yamamoto, T. T. (2001).
Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxida-
tion of acetate. J. Biol. Chem. 276, 11420–11426. doi: 10.1074/jbc.M008782200
Gibbs, E. M., Feldman, E. L., and Dowling, J. J. (2010). The role of
MTMR14 in autophagy and in muscle disease. Autophagy 6, 819–820. doi:
10.4161/auto.6.6.12624
Goldberg, A. L., Tischler, M., DeMartino, G., and Griffin, G. (1980). Hormonal
regulation of protein degradation and synthesis in skeletal muscle. Fed. Proc. 39,
31–36.
Gonzalez, E., and Delbono, O. (2001a). Age-dependent fatigue in single intact fast-
and slow fibers from mouse EDL and soleus skeletal muscles.Mech. Ageing Dev.
122, 1019–1032. doi: 10.1016/S0047-6374(01)00229-9
Gonzalez, E., and Delbono, O. (2001b). Recovery from fatigue in fast and slow sin-
gle intact skeletal muscle fibers from aging mouse.Muscle Nerve 24, 1219–1224.
doi: 10.1002/mus.1135
Gonzalez, E., Messi, M. L., and Delbono, O. (2000). The specific force of single
intact extensor digitorum longus and soleus mouse muscle fibers declines with
aging. J. Membr. Biol. 178, 175–183. doi: 10.1007/s002320010025
Gonzalez-Reimers, E., Duran-Castellon, M. C., Lopez-Lirola, A., Santolaria-
Fernandez, F., Abreu-Gonzalez, P., Alvisa-Negrin, J., et al. (2010). Alcoholic
myopathy: vitamin D deficiency is related to muscle fibre atrophy in a murine
model. Alcohol Alcohol. 45, 223–230. doi: 10.1093/alcalc/agq010
Gray, S., Wang, B., Orihuela, Y., Hong, E. G., Fisch, S., Haldar, S., et al. (2007).
Regulation of gluconeogenesis by Kruppel-like factor 15.Cell Metab. 5, 305–312.
doi: 10.1016/j.cmet.2007.03.002
Haldar, S. M., Ibrahim, O. A., and Jain, M. K. (2007). Kruppel-like
Factors (KLFs) in muscle biology. J. Mol. Cell. Cardiol. 43, 1–10. doi:
10.1016/j.yjmcc.2007.04.005
Haldar, S. M., Jeyaraj, D., Anand, P., Zhu, H., Lu, Y., Prosdocimo, D. A.,
et al. (2012). Kruppel-like factor 15 regulates skeletal muscle lipid flux
and exercise adaptation. Proc. Natl. Acad. Sci. U.S.A. 109, 6739–6744. doi:
10.1073/pnas.1121060109
Hofer, T., Badouard, C., Bajak, E., Ravanat, J. L., Mattsson, A., and Cotgreave, I. A.
(2005). Hydrogen peroxide causes greater oxidation in cellular RNA than in
DNA. Biol. Chem. 386, 333–337. doi: 10.1515/BC.2005.040
Hong-Brown, L. Q., Brown, C. R., Huber, D. S., and Lang, C. H. (2006). Alcohol
and indinavir adversely affect protein synthesis and phosphorylation of MAPK
and mTOR signaling pathways in C2C12 myocytes. Alcohol. Clin. Exp. Res. 30,
1297–1307. doi: 10.1111/j.1530-0277.2006.00157.x
Jungbluth, H., Wallgren-Pettersson, C., and Laporte, J. (2008). Centronuclear
(myotubular) myopathy. Orphanet J. Rare Dis. 3, 26. doi: 10.1186/1750-
1172-3-26
Lang, C. H., Frost, R. A., Deshpande, N., Kumar, V., Vary, T. C., Jefferson, L. S., et al.
(2003). Alcohol impairs leucine-mediated phosphorylation of 4E-BP1, S6K1,
eIF4G, and mTOR in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 285,
E1205–E1215. doi: 10.1152/ajpendo.00177.2003
Lang, C. H., Wu, D., Frost, R. A., Jefferson, L. S., Kimball, S. R., and Vary, T. C.
(1999). Inhibition of muscle protein synthesis by alcohol is associated with
modulation of eIF2B and eIF4E. Am. J. Physiol. 277(2 Pt 1), E268–E276.
Laporte, J., Bedez, F., Bolino, A., and Mandel, J. L. (2003). Myotubularins, a large
disease-associated family of cooperating catalytically active and inactive phos-
phoinositides phosphatases. Hum. Mol. Genet. 12(Spec No 2), R285–R292. doi:
10.1093/hmg/ddg273
Laporte, J., Hu, L. J., Kretz, C., Mandel, J. L., Kioschis, P., Coy, J. F., et al. (1996).
A gene mutated in X-linked myotubular myopathy defines a new putative
tyrosine phosphatase family conserved in yeast. Nat. Genet. 13, 175–182. doi:
10.1038/ng0696-175
Leberer, E., Charuk, J. H., Green, N. M., and MacLennan, D. H. (1989). Molecular
cloning and expression of cDNA encoding a lumenal calcium binding glycopro-
tein from sarcoplasmic reticulum. Proc. Natl. Acad. Sci. U.S.A. 86, 6047–6051.
doi: 10.1073/pnas.86.16.6047
Leberer, E., Timms, B. G., Campbell, K. P., and MacLennan, D. H. (1990).
Purification, calcium binding properties, and ultrastructural localization of the
53, 000- and 160, 000 (sarcalumenin)-dalton glycoproteins of the sarcoplasmic
reticulum. J. Biol. Chem. 265, 10118–10124.
Lewis, R. S. (2007). The molecular choreography of a store-operated calcium
channel. Nature 446, 284–287. doi: 10.1038/nature05637
Lexell, J. (1993). Ageing and human muscle: observations from Sweden. Can. J.
Appl. Physiol. 18, 2–18. doi: 10.1139/h93-002
Lofberg, E., Gutierrez, A., Wernerman, J., Anderstam, B., Mitch, W. E., Price, S. R.,
et al. (2002). Effects of high doses of glucocorticoids on free amino acids, ribo-
somes and protein turnover in human muscle. Eur. J. Clin. Invest. 32, 345–353.
doi: 10.1046/j.1365-2362.2002.00993.x
Lowe, D. A., Husom, A. D., Ferrington, D. A., and Thompson, L. V. (2004).
Myofibrillar myosin ATPase activity in hindlimb muscles from young and aged
rats. Mech. Ageing Dev. 125, 619–627. doi: 10.1016/j.mad.2004.07.002
Lowe, D. A., Thomas, D. D., and Thompson, L. V. (2002). Force generation, but not
myosin ATPase activity, declines with age in rat muscle fibers.Am. J. Physiol. Cell
Physiol. 283, C187–C192. doi: 10.1152/ajpcell.00008.2002
Ma, J., and Pan, Z. (2003). Retrograde activation of store-operated calcium channel.
Cell Calcium 33, 375–384. doi: 10.1016/S0143-4160(03)00050-2
Ma, R., Du, J., Sours, S., and Ding,M. (2006). Store-operated Ca2+ channel in renal
microcirculation and glomeruli. Exp. Biol. Med. (Maywood) 231, 145–153.
Manini, T.M., and Clark, B. C. (2012). Dynapenia and aging: an update. J. Gerontol.
A Biol. Sci. Med. Sci. 67, 28–40. doi: 10.1093/gerona/glr010
Mitchell, W. K., Williams, J., Atherton, P., Larvin, M., Lund, J., and Narici, M.
(2012). Sarcopenia, dynapenia, and the impact of advancing age on human
skeletal muscle size and strength; a quantitative review. Front. Physiol. 3:260.
doi: 10.3389/fphys.2012.00260
Murray, C. J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., et al.
(2010). Disability-adjusted life years (DALYs) for 291 diseases and injuries in
21 regions, 1990-2010, a systematic analysis for the Global Burden of Disease
Study. Lancet 380, 2197–2223. doi: 10.1016/S0140-6736(12)61689-4
Nagaraj, R. Y., Nosek, C. M., Brotto, M. A., Nishi, M., Takeshima, H., Nosek, T. M.,
et al. (2000). Increased susceptibility to fatigue of slow- and fast-twitch muscles
from mice lacking the MG29 gene. Physiol. Genomics 4, 43–49.
Nakahara, T., Hashimoto, K., Hirano, M., Koll, M., Martin, C. R., and Preedy, V. R.
(2003). Acute and chronic effects of alcohol exposure on skeletal muscle c-myc,
Frontiers in Physiology | Striated Muscle Physiology February 2014 | Volume 5 | Article 37 | 10
Manring et al. ECC genes in muscle weakness
p53, and Bcl-2 mRNA expression. Am. J. Physiol. Endocrinol. Metab. 285,
E1273–E1281. doi: 10.1152/ajpendo.00019.2003
Nakahara, T., Hunter, R., Hirano, M., Uchimura, H., McArdle, A., Broome, C. S.,
et al. (2006). Alcohol alters skeletal muscle heat shock protein gene expres-
sion in rats: these effects are moderated by sex, raised endogenous acetalde-
hyde, and starvation. Metabolism 55, 843–851. doi: 10.1016/j.metabol.2006.
02.009
Nilius, B. (2004). Store-operated Ca2+ entry channels: still elusive! Sci. STKE 2004,
pe36. doi: 10.1126/stke.2342004pe36
Nishi, M., Komazaki, S., Kurebayashi, N., Ogawa, Y., Noda, T., Iino, M., et al.
(1999). Abnormal features in skeletal muscle from mice lacking mitsugumin29.
J. Cell Biol. 147, 1473–1480. doi: 10.1083/jcb.147.7.1473
Noordzij, M., Boeschoten, E. W., Bos, W. J., Dekker, F. W., Bossuyt, P. M., Krediet,
R. T., et al. (2007). Disturbed mineral metabolism is associated with muscle
and skin complaints in a prospective cohort of dialysis patients. Nephrol. Dial.
Transplant 22, 2944–2949. doi: 10.1093/ndt/gfm319
O’Connell, K., Gannon, J., Doran, P., and Ohlendieck, K. (2008). Reduced expres-
sion of sarcalumenin and related Ca2+ -regulatory proteins in aged rat skeletal
muscle. Exp. Gerontol. 43, 958–961. doi: 10.1016/j.exger.2008.07.006
Pan, Z., Yang, D., Nagaraj, R. Y., Nosek, T. A., Nishi, M., Takeshima, H., et al. (2002).
Dysfunction of store-operated calcium channel in muscle cells lacking mg29.
Nat. Cell Biol. 4, 379–383. doi: 10.1038/ncb788
Parekh, A. B., and Putney, J.W. Jr. (2005). Store-operated calcium channels. Physiol.
Rev. 85, 757–810. doi: 10.1152/physrev.00057.2003
Pearson, R., Fleetwood, J., Eaton, S., Crossley, M., and Bao, S. (2008). Kruppel-
like transcription factors: a functional family. Int. J. Biochem. Cell Biol. 40,
1996–2001. doi: 10.1016/j.biocel.2007.07.018
Pierson, C. R., Tomczak, K., Agrawal, P., Moghadaszadeh, B., and Beggs, A. H.
(2005). X-linked myotubular and centronuclear myopathies. J. Neuropathol.
Exp. Neurol. 64, 555–564. doi: 10.1097/01.jnen.0000171653.17213.2e
Place, N., Bruton, J. D., and Westerblad, H. (2009). Mechanisms of fatigue induced
by isometric contractions in exercising humans and in mouse isolated single
muscle fibres. Clin. Exp. Pharmacol. Physiol. 36, 334–339. doi: 10.1111/j.1440-
1681.2008.05021.x
Preedy, V. R., Adachi, J., Ueno, Y., Ahmed, S., Mantle, D., Mullatti, N., et al.
(2001a). Alcoholic skeletal muscle myopathy: definitions, features, contribu-
tion of neuropathy, impact and diagnosis. Eur. J. Neurol. 8, 677–687. doi:
10.1046/j.1468-1331.2001.00303.x
Preedy, V. R., Paice, A., Mantle, D., Dhillon, A. S., Palmer, T. N., and Peters, T. J.
(2001b). Alcoholic myopathy: biochemical mechanisms. Drug Alcohol Depend.
63, 199–205. doi: 10.1016/S0376-8716(00)00219-2
Preedy, V. R., and Peters, T. J. (1988). The effect of chronic ethanol ingestion on
protein metabolism in type-I- and type-II-fibre-rich skeletal muscles of the rat.
Biochem. J. 254, 631–639.
Putney, J. W. Jr., Broad, L. M., Braun, F. J., Lievremont, J. P., and Bird, G. S. (2001).
Mechanisms of capacitative calcium entry. J. Cell Sci. 114(Pt 12), 2223–2229.
Rahimov, F., and Kunkel, L. M. (2013). The cell biology of disease: cellular
and molecular mechanisms underlying muscular dystrophy. J. Cell Biol. 201,
499–510. doi: 10.1083/jcb.201212142
Romanick, M., Thompson, L. V., and Brown-Borg, H. M. (2013). Murine models
of atrophy, cachexia, and sarcopenia in skeletal muscle. Biochim. Biophys. Acta
1832, 1410–1420. doi: 10.1016/j.bbadis.2013.03.011
Romero, N. B. (2010). Centronuclear myopathies: a widening concept.
Neuromuscul. Disord. 20, 223–228. doi: 10.1016/j.nmd.2010.01.014
Romero, N. B., and Bitoun, M. (2011). Centronuclear myopathies. Semin. Pediatr.
Neurol. 18, 250–256. doi: 10.1016/j.spen.2011.10.006
Romero-Suarez, S., Shen, J., Brotto, L., Hall, T., Mo, C., Valdivia, H. H., et al. (2010).
Muscle-specific inositide phosphatase (MIP/MTMR14) is reduced with age and
its loss accelerates skeletal muscle aging process by altering calcium homeostasis.
Aging (Albany NY). 2, 504–513.
Rossi, A. E., and Dirksen, R. T. (2006). Sarcoplasmic reticulum: the dynamic
calcium governor of muscle.Muscle Nerve 33, 715–731. doi: 10.1002/mus.20512
Russ, D. W., Gregg-Cornell, K., Conaway, M. J., and Clark, B. C. (2012) Evolving
concepts on the age-related changes in “muscle quality.” J. Cachexia Sarcopenia
Muscle 3, 95–109. doi: 10.1007/s13539-011-0054-2
Schakman, O., Kalista, S., Barbe, C., Loumaye, A., and Thissen, J. P. (2013).
Glucocorticoid-induced skeletal muscle atrophy. Int. J. Biochem. Cell Biol. 45,
2163–2172. doi: 10.1016/j.biocel.2013.05.036
Sewry, C. A. (2008). Pathological defects in congenital myopathies. J. Muscle Res.
Cell Motil. 29, 231–238. doi: 10.1007/s10974-008-9155-8
Shen, J., Yu, W. M., Brotto, M., Scherman, J. A., Guo, C., Stoddard, C., et al.
(2009). Deficiency of MIP/MTMR14 phosphatase induces a muscle disorder
by disrupting Ca(2+) homeostasis. Nat. Cell Biol. 11, 769–776. doi: 10.1038/nc
b1884
Shimizu, N., Yoshikawa, N., Ito, N., Maruyama, T., Suzuki, Y., Takeda, S.,
et al. (2011). Crosstalk between glucocorticoid receptor and nutritional sensor
mTOR in skeletal muscle. Cell Metab. 13, 170–182. doi: 10.1016/j.cmet.2011.
01.001
Smaili, S. S., Pereira, G. J., Costa, M. M., Rocha, K. K., Rodrigues, L., do Carmo, L.
G., et al. (2013). The role of calcium stores in apoptosis and autophagy. Curr.
Mol. Med. 13, 252–265. doi: 10.2174/156652413804810772
Takeshima, H., Shimuta, M., Komazaki, S., Ohmi, K., Nishi, M., Iino, M., et al.
(1998). Mitsugumin29, a novel synaptophysin family member from the triad
junction in skeletal muscle. Biochem. J. 331(Pt 1), 317–322.
Targos, B., Baranska, J., and Pomorski, P. (2005). Store-operated calcium entry
in physiology and pathology of mammalian cells. Acta Biochim. Pol. 52,
397–409.
Teixeira Vde, O., Filippin, L. I., and Xavier, R. M. (2012). Mechanisms of muscle
wasting in sarcopenia. Rev. Bras. Reumatol. 52, 252–259. doi: 10.1590/S0482-
50042012000200009
Thiele, C., Hannah, M. J., Fahrenholz, F., and Huttner, W. B. (2000). Cholesterol
binds to synaptophysin and is required for biogenesis of synaptic vesicles. Nat.
Cell Biol. 2, 42–49. doi: 10.1038/71366
Thomas, L., and Betz, H. (1990). Synaptophysin binds to physophilin, a putative
synaptic plasma membrane protein. J. Cell Biol. 111(5 Pt 1), 2041–2052. doi:
10.1083/jcb.111.5.2041
Thomas, L., Hartung, K., Langosch, D., Rehm, H., Bamberg, E., Franke, W. W.,
et al. (1988). Identification of synaptophysin as a hexameric channel protein
of the synaptic vesicle membrane. Science 242, 1050–1053. doi: 10.1126/sci-
ence.2461586
Thomas, S. G., Takahashi, M., Neill, J. D., and Clarke, I. J. (1998). Components
of the neuronal exocytotic machinery in the anterior pituitary of the ovariec-
tomised ewe and the effects of oestrogen in gonadotropes as studied with
confocal microscopy. Neuroendocrinology 67, 244–259. doi: 10.1159/0000
54320
Tomas, F. M., Munro, H. N., and Young, V. R. (1979). Effect of glucocorti-
coid administration on the rate of muscle protein breakdown in vivo in rats,
as measured by urinary excretion of N tau-methylhistidine. Biochem. J. 178,
139–146.
Tosch, V., Rohde, H. M., Tronchere, H., Zanoteli, E., Monroy, N., Kretz, C., et al.
(2006). A novel PtdIns3P and PtdIns(3, 5)P2 phosphatase with an inactivat-
ing variant in centronuclear myopathy. Hum. Mol. Genet. 15, 3098–3106. doi:
10.1093/hmg/ddl250
Turner, J., and Crossley, M. (1999). Basic Kruppel-like factor functions within a
network of interacting haematopoietic transcription factors. Int. J. Biochem. Cell
Biol. 31, 1169–1174. doi: 10.1016/S1357-2725(99)00067-9
Urbano-Marquez, A., Estruch, R., Fernandez-Sola, J., Nicolas, J. M., Pare, J.
C., and Rubin, E. (1995). The greater risk of alcoholic cardiomyopathy
and myopathy in women compared with men. JAMA 274, 149–154. doi:
10.1001/jama.1995.03530020067034
Urbano-Marquez, A., and Fernandez-Sola, J. (2004). Effects of alcohol on skeletal
and cardiac muscle. Muscle Nerve 30, 689–707. doi: 10.1002/mus.20168
Vergne, I., Roberts, E., Elmaoued, R. A., Tosch, V., Delgado, M. A., Proikas-
Cezanne, T., et al. (2009). Control of autophagy initiation by phospho-
inositide 3-phosphatase Jumpy. EMBO J. 28, 2244–2258. doi: 10.1038/emboj.
2009.159
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M.,
et al. (2010). Years lived with disability (YLDs) for 1160 sequelae of 289 dis-
eases and injuries 1990-2010, a systematic analysis for the Global Burden
of Disease Study. Lancet 380, 2163–2196. doi: 10.1016/S0140-6736(12)61
729-2
Wallgren-Pettersson, C., Clarke, A., Samson, F., Fardeau, M., Dubowitz, V.,
Moser, H., et al. (1995). The myotubular myopathies: differential diagno-
sis of the X linked recessive, autosomal dominant, and autosomal recessive
forms and present state of DNA studies. J. Med. Genet. 32, 673–679. doi:
10.1136/jmg.32.9.673
www.frontiersin.org February 2014 | Volume 5 | Article 37 | 11
Manring et al. ECC genes in muscle weakness
Weisleder, N., Brotto, M., Komazaki, S., Pan, Z., Zhao, X., Nosek, T., et al.
(2006). Muscle aging is associated with compromised Ca2+ spark signal-
ing and segregated intracellular Ca2+ release. J. Cell Biol. 174, 639–645. doi:
10.1083/jcb.200604166
Wishart, M. J., and Dixon, J. E. (2002). PTEN and myotubularin phosphatases:
from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol. 12,
579–585. doi: 10.1016/S0962-8924(02)02412-1
Yamamoto, J., Ikeda, Y., Iguchi, H., Fujino, T., Tanaka, T., Asaba, H., et al. (2004).
A Kruppel-like factor KLF15 contributes fasting-induced transcriptional acti-
vation of mitochondrial acetyl-CoA synthetase gene AceCS2. J. Biol. Chem. 279,
16954–16962. doi: 10.1074/jbc.M312079200
Yoshida, M., Minamisawa, S., Shimura, M., Komazaki, S., Kume, H., Zhang, M.,
et al. (2005). Impaired Ca2+ store functions in skeletal and cardiac muscle
cells from sarcalumenin-deficient mice. J. Biol. Chem. 280, 3500–3506. doi:
10.1074/jbc.M406618200
Zahn, J. M., Sonu, R., Vogel, H., Crane, E., Mazan-Mamczarz, K., Rabkin, R.,
et al. (2006). Transcriptional profiling of aging in human muscle reveals a
common aging signature. PLoS Genet. 2:e115. doi: 10.1371/journal.pgen.00
20115
Zhao, X., Weisleder, N., Thornton, A., Oppong, Y., Campbell, R., Ma,
J., et al. (2008). Compromised store-operated Ca2+ entry in aged
skeletal muscle. Aging Cell 7, 561–568. doi: 10.1111/j.1474-9726.2008.
00408.x
Zhao, X., Yoshida, M., Brotto, L., Takeshima, H., Weisleder, N., Hirata, Y., et al.
(2005). Enhanced resistance to fatigue and altered calcium handling properties
of sarcalumenin knockoutmice. Physiol. Genomics 23, 72–78. doi: 10.1152/phys-
iolgenomics.00020.2005
Zhu, X., and Birnbaumer, L. (1998). Calcium channels formed by mammalian Trp
homologues. News Physiol. Sci. 13, 211–217.
Conflict of Interest Statement: Dr. Noah Weisleder is the Founder and Chief
Scientific Officer of TRIM-edicine, a biotechnology company developing protein
therapeutic agents. The other authors declare that the research was conducted in
the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 31 October 2013; paper pending published: 19 November 2013; accepted: 18
January 2014; published online: 18 February 2014.
Citation: Manring H, Abreu E, Brotto L, Weisleder N and Brotto M (2014) Novel
excitation-contraction coupling related genes reveal aspects of muscle weakness beyond
atrophy—new hopes for treatment of musculoskeletal diseases. Front. Physiol. 5:37.
doi: 10.3389/fphys.2014.00037
This article was submitted to Striated Muscle Physiology, a section of the journal
Frontiers in Physiology.
Copyright © 2014 Manring, Abreu, Brotto, Weisleder and Brotto. This is an open-
access article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Physiology | Striated Muscle Physiology February 2014 | Volume 5 | Article 37 | 12
